CD274 and non-small cell lung carcinoma: Preliminary data showed that compared with platinum-doublet chemotherapy, cemiplimab provided superior OS (median, NR vs. 14.2 months; HR, 0.57; 95% CI, 0.42–0.77) and PFS (median, 8.2 vs. 5.7 months; HR, 0.54; 95% CI, 0.43–0.68) in patients with NSCLC expressing high PD-L1 levels.